Arcutis Biotherapeutics, Inc. (ARQT) stock
Close on Nov 11, 2026Market cap $3.57BP/E 129.0Yield –
Arcutis Biotherapeutics, Inc. grew revenue 60.0% to $508.68M over the twelve months to Sep 30, 2026. Free cash flow was $59.71M. At the latest close the market valued the company at $3.57B, 129.0 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $3.57B
- P/E ratio
- 129.0
- Price to sales
- 7.01
- Price to book
- 14.62
- Dividend yield
- –
- Free cash flow yield
- 1.67%
Fundamentals
- Revenue
- $508.68M
- Net income
- $29.91M
- EPS, diluted
- $0.22
- Free cash flow
- $59.71M
- Book value per share
- $1.78
- Diluted shares
- 137M
Trading
- Next earnings
- Feb 24, 2027 (estimated, after the close)
- Previous close
- $27.39
- Open
- $27.50
- Day's range
- $27.20 – $28.65
- Volume
- 2,490,617
- Average volume (20 days)
- 2,750,176
- Index membership
- Russell 2000 (since Mar 2020), Russell 3000 (since Feb 2020)
- Beta (5 years)
- 0.92
- 52-week range
- $19.30 – $34.80
- RSI (14 days)
- 48.3
- Volatility (1 year)
- 56.4%
- Relative volume
- 1.08×
- WACC
- 9.5%
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | ARQT | S&P 500 | Difference | ARQT per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +6.8% | -2.4% | +9.2 pts | ||
| 3 months | +8.2% | -1.2% | +9.3 pts | ||
| Year to date | -2.3% | +12.3% | −14.6 pts | ||
| 1 year | +18.1% | +12.4% | +5.7 pts | ||
| 3 years | +1389.8% | +78.8% | +1311.0 pts | +146.1% | +21.4% |
| 5 years | +33.6% | +75.2% | −41.6 pts | +6.0% | +11.9% |
Nine years at a glance
Fiscal years 2017 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Arcutis Biotherapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Results
- Update
- Results
- Update
About Arcutis Biotherapeutics
Pharmaceutical Preparations
This commercial-stage biopharmaceutical enterprise develops and markets treatments for immune-mediated skin disorders. The business concentrates on dermatological therapies, offering topical roflumilast formulations under the ZORYVE brand in cream and foam formats. These commercialized products are prescribed for conditions including plaque psoriasis, atopic dermatitis, and seborrheic dermatitis across various adult and pediatric age groups. In addition to commercial assets, development efforts encompass an experimental biologic fusion protein, ARQ-234, aimed at inflammatory conditions. Target prescribers and healthcare customers primarily include dermatologists, pediatricians, and primary care physicians caring for patients with chronic inflammatory skin diseases.
Company profile, executives and historyArcutis Biotherapeutics stock: common questions
What is Arcutis Biotherapeutics's stock price?
ARQT closed at $28.38 on Nov 11, 2026, up 3.63% on the day. Over the past 52 weeks it traded between $19.30 and $34.80.
What is Arcutis Biotherapeutics's market cap?
Arcutis Biotherapeutics was worth $3.57B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is ARQT's P/E ratio?
ARQT trades at 129.0 times earnings, based on diluted earnings per share of $0.22 over the twelve months to Sep 30, 2026.
How much revenue does Arcutis Biotherapeutics make?
Arcutis Biotherapeutics reported revenue of $508.68M for the twelve months to Sep 30, 2026, up 60.0% from a year earlier.
Does Arcutis Biotherapeutics pay a dividend?
No. Arcutis Biotherapeutics has not paid a cash dividend over the last twelve months.
When does Arcutis Biotherapeutics report earnings next?
Arcutis Biotherapeutics is expected to report Q4 FY2026 results on Feb 24, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has ARQT stock performed over the past year?
Including dividends, ARQT returned +18.1% over the past year, against +12.4% for the S&P 500.
How many ARQT shares are sold short?
18M shares were sold short at the latest FINRA report, 15.93% of the float, or 7.6 days of average trading volume.
Who are Arcutis Biotherapeutics's competitors?
Companies most similar to Arcutis Biotherapeutics by business, industry and size include ARDX, ZLAB, AAPG, HCM, PTGX.
See a number that looks wrong?